Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 4/20 | 0.75 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.75 |
| ▸ | SRC | P12931 | 2/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.75 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.75 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.75 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.75 |
| ▸ | LDHA | P00338 | 1/20 | 0.75 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.75 |
| ▸ | FBP1 | P09467 | 1/20 | 0.75 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.75 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.75 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.75 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.75 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.75 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.75 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.75 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.75 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.75 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenosine Phosphate SCHEMBL27419541 | 1.00 | P2RY1 (0.75) | P2RY1P2RY2SRCSMN1; SMN2DNPH1 | |
| Adenosine Diphosphate SCHEMBL570243 | 0.94 | ADH1A (0.74) | P2RY1P2RY2SRCSMN1; SMN2TRPM2 | |
| Adenosine Phosphate SCHEMBL810818 | 0.94 | DNPH1 (0.75) | P2RY1P2RY2SRCSMN1; SMN2DNPH1 | |
| Adenosine Triphosphate SCHEMBL811698 | 0.93 | ADH1A (0.75) | P2RY1P2RY2SRCSMN1; SMN2TRPM2 | |
| Niacinamide SCHEMBL6233231 | 0.93 | ADORA1 (0.64) | P2RY1P2RY2SRCSMN1; SMN2DNPH1 | |
| Adenosine SCHEMBL5981999 | 0.90 | ADORA1 (0.65) | P2RY1P2RY2SRCSMN1; SMN2DNPH1 | |
| Niacinamide SCHEMBL28249016 | 0.89 | ADH1A (0.66) | P2RY1P2RY2SRCSMN1; SMN2TRPM2 | |
| Adenosine Phosphate SCHEMBL7672973 | 0.88 | P2RY1 (0.89) | P2RY1P2RY2SRCSMN1; SMN2DNPH1 | |
| Adenosine Phosphate SCHEMBL790420 | 0.88 | P2RY1 (0.92) | P2RY1P2RY2SRCSMN1; SMN2DNPH1 | |
| SCHEMBL810819 | 0.88 | P2RY1 (0.69) | P2RY1P2RY2SRCSMN1; SMN2DNPH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119709792-A | Recombinant bacterium for producing nicotinamide mononucleotide as well as preparation method and application thereof | 赛诺根生物科学有限公司 | 2025-03-28 | — | — | CN | claimed |
| US-20090325923-A1 | NEW METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES | TOPOTARGET SWITZERLAND SA (CH) | 2009-12-31 | — | — | US | claimed |
| WO-2009109610-A1 | USE OF NAD INFORMATION INHIBITORS FOR THE TREATMENT OF ISCHEMIA-REPERFUSION INJURY | TOPOTARGET SWITZERLAND S.A. (CH) | 2009-09-11 | — | — | WO | claimed |
| EP-2073808-A2 | NEW METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES | Topotarget Switzerland SA (CH) | 2009-07-01 | — | — | EP | claimed |
| WO-2008025857-A2 | NEW METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES | TOPOTARGET SWITZERLAND SA (CH) | 2008-03-06 | — | — | WO | claimed |
| WO-2008026018-A1 | NEW METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES | TOPOTARGET SWITZERLAND SA (CH) | 2008-03-06 | — | — | WO | claimed |
| CN-119709792-A | Recombinant bacterium for producing nicotinamide mononucleotide as well as preparation method and application thereof | 赛诺根生物科学有限公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-119709792-A | Recombinant bacterium for producing nicotinamide mononucleotide as well as preparation method and application thereof | 赛诺根生物科学有限公司 | 2025-03-28 | — | — | CN | disclosed |
| WO-2023229346-A1 | NOVEL COMPOUND FOR INHIBITING NAMPT, AND COMPOSITION INCLUDING SAME | 주식회사 체크메이트테라퓨틱스 | 2023-11-30 | — | — | WO | disclosed |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO HEALTH, INC. | 2023-11-02 | — | — | US | disclosed |
| US-11795163-B2 | Compound for inhibiting nicotinamide phosphoribosyltransferase and composition containing same | CHECKMATE THERAPEUTICS INC. | 2023-10-24 | — | — | US | disclosed |
| EP-3431472-B1 | NOVEL COMPOUND FOR INHIBITING NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE AND COMPOSITION CONTAINING SAME | CHECKMATE THERAPEUTICS INC (KR) | 2023-05-03 | — | — | EP | disclosed |
| US-20230110003-A1 | PIPERIDINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) | Valo Health, LLC | 2023-04-13 | — | — | US | disclosed |
| US-20060211752-A1 | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression | BENAVIDES-PERALTA, URUGUAYSITO LORELEY (UY) | 2006-09-21 | — | — | US | disclosed |
| US-20060147508-A1 | Concurrent Enhancement of Skin Penetration of Organic Base Active Agents and Organic Hydroxy Acid Active Agents as Their Ion-Pair Complexes | BIODERM RESEARCH (US) | 2006-07-06 | — | — | US | disclosed |
| US-20040081672-A1 | Niacinamide, niacin, and niacin esters based delivery systems for treating topical disorders of skin and skin aging | GUPTA SHYAM K (US) | 2004-04-29 | — | — | US | disclosed |
| US-5053396-A | For treatment of symptoms associated with excessive alcohol intake, analgesic; nicotinamide or nicotinamide adenine dinucleotide | BLASS DAVID H (GB) | 1991-10-01 | — | — | US | disclosed |
| EP-0271489-B1 | THERAPEUTIC COMPOSITION | BLASS, David Henry (GB) | 1990-02-28 | — | — | EP | disclosed |
| EP-0271489-A1 | THERAPEUTIC COMPOSITION. | BLASS DAVID HENRY | 1988-06-22 | — | — | EP | disclosed |
| WO-1987001285-A1 | THERAPEUTIC COMPOSITION | BLASS DAVID HENRY (GB) | 1987-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211752-A1 | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression | TLR3, IRF3, TLR4 | P2RY1 397/4885P2RY2 711/4885SRC 575/4885 |
| US-20230110003-A1 | PIPERIDINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) | NAMPT, NAPRT, NNMT | P2RY1 118/4885P2RY2 187/4885SRC 4846/4885 |
| US-11795163-B2 | Compound for inhibiting nicotinamide phosphoribosyltransferase and composition containing same | NAMPT, NAPRT, NNT | P2RY1 495/4885P2RY2 681/4885SRC 3775/4885 |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | P2RY1 458/4885P2RY2 529/4885SRC 4843/4885 |
| US-20090325923-A1 | NEW METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES | NAMPT, NNMT, NQO2 | P2RY1 105/4885P2RY2 183/4885SRC 3894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.